Dacarbazine medac 500 mg, powder for solution for infusion
Authorisation PA0623/003/003 · medac Gesellschaft für klinische Spezialpräparate mbH
- Licence holder
- medac Gesellschaft für klinische Spezialpräparate mbH (all products →)
- Active substance
- Dacarbazine
- Clinical trials
- 24 clinical trials →
- Dosage form
- Powder for solution for infusion
- Route of administration
- Intravenous use
- ATC codes
- L01AX, L01AX04
- First authorised
- 14/11/1997
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Well-established use application (Article 10a of Directive No 2001/83/EC)
Dacarbazine: supply and approvals
6 authorised products on the HPRA list contain Dacarbazine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- 1 supply notice, e.g. Dacarbazin Lipomed 1000 mg Pulver zur Herstellung einer Infusionslösung (31 Oct 2026 to 15 Dec 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 29 years (since 14 November 1997). The HPRA list marks it as marketed in Ireland.
Other medicines with Dacarbazine in Ireland
5 other products on the HPRA list contain Dacarbazine, from 2 licence holders; 5 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Dacarbazine Lipomed 1000 mg powder for solution for infusion | Lipomed GmbH | National authorisation (PA) | Marketed |
| Dacarbazine Lipomed 200 mg powder for solution for injection or infusion | Lipomed GmbH | National authorisation (PA) | Marketed |
| Dacarbazine Lipomed 500 mg powder for solution for infusion | Lipomed GmbH | National authorisation (PA) | Marketed |
| Dacarbazine medac 1000 mg, powder for solution for infusion | medac Gesellschaft für klinische Spezialpräparate mbH | National authorisation (PA) | Marketed |
| Dacarbazine medac 200 mg, powder for solution for injection/infusion | medac Gesellschaft für klinische Spezialpräparate mbH | National authorisation (PA) | Marketed |
Other substances in ATC group L01AX
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 1 other active substance shares the group L01AX with this product:
Temozolomide (31)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
medac Gesellschaft für klinische Spezialpräparate mbH holds 28 products on the HPRA list, with 13 different active substances; 10 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.